Stan Bukofzer

863 total citations
21 papers, 612 citations indexed

About

Stan Bukofzer is a scholar working on Hepatology, Surgery and Epidemiology. According to data from OpenAlex, Stan Bukofzer has authored 21 papers receiving a total of 612 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hepatology, 6 papers in Surgery and 6 papers in Epidemiology. Recurrent topics in Stan Bukofzer's work include Liver Disease and Transplantation (7 papers), Liver Disease Diagnosis and Treatment (5 papers) and Organ Transplantation Techniques and Outcomes (5 papers). Stan Bukofzer is often cited by papers focused on Liver Disease and Transplantation (7 papers), Liver Disease Diagnosis and Treatment (5 papers) and Organ Transplantation Techniques and Outcomes (5 papers). Stan Bukofzer collaborates with scholars based in United States, United Kingdom and South Africa. Stan Bukofzer's co-authors include Michael C. Kew, Anna Kramvis, Michael George, Eugene Dula, Renee Perdok, Bruce E. McNutt, E Song, Bruce M. Prenner, Ann M. Ginsberg and H. J. W. Thomas and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Hepatology.

In The Last Decade

Stan Bukofzer

21 papers receiving 593 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stan Bukofzer United States 13 159 146 130 115 105 21 612
Zhangyan Lyu China 14 199 1.3× 14 0.1× 13 0.1× 48 0.4× 82 0.8× 55 828
K. Beckh Germany 12 92 0.6× 66 0.5× 8 0.1× 24 0.2× 107 1.0× 36 518
Massimo Tartagni Italy 19 47 0.3× 48 0.3× 11 0.1× 161 1.4× 61 0.6× 41 1.1k
Georgina R. Hogg Canada 12 91 0.6× 8 0.1× 78 0.6× 51 0.4× 33 0.3× 16 571
Jens Drube Germany 16 54 0.3× 23 0.2× 32 0.2× 31 0.3× 48 0.5× 33 662
Masakatsu Uchihara Japan 13 423 2.7× 565 3.9× 40 0.3× 26 0.2× 31 0.3× 36 746
Jianwei Chen China 14 60 0.4× 83 0.6× 20 0.2× 5 0.0× 28 0.3× 30 644
Socrate Pallio Italy 15 121 0.8× 37 0.3× 14 0.1× 12 0.1× 29 0.3× 61 676
Jakub Ząbek Poland 12 85 0.5× 21 0.1× 21 0.2× 42 0.4× 105 1.0× 40 498
Lothar C. Fuith Austria 11 116 0.7× 11 0.1× 28 0.2× 31 0.3× 26 0.2× 33 762

Countries citing papers authored by Stan Bukofzer

Since Specialization
Citations

This map shows the geographic impact of Stan Bukofzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stan Bukofzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stan Bukofzer more than expected).

Fields of papers citing papers by Stan Bukofzer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stan Bukofzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stan Bukofzer. The network helps show where Stan Bukofzer may publish in the future.

Co-authorship network of co-authors of Stan Bukofzer

This figure shows the co-authorship network connecting the top 25 collaborators of Stan Bukofzer. A scholar is included among the top collaborators of Stan Bukofzer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stan Bukofzer. Stan Bukofzer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bukofzer, Stan, et al.. (2023). OCE-205, a Selective V1a Partial Agonist, Reduces Portal Pressure in Rat Models of Portal Hypertension. Journal of Experimental Pharmacology. Volume 15. 279–290. 2 indexed citations
2.
Fernández‐Varo, Guillermo, Wladimiro Jiménez, Edward Cable, et al.. (2023). Partial vasopressin 1a receptor agonism reduces portal hypertension and hyperaldosteronism and induces a powerful diuretic and natriuretic effect in rats with cirrhosis and ascites. Biomedicine & Pharmacotherapy. 165. 115116–115116. 2 indexed citations
3.
Bagger, Yu Z., William R. Ravis, Geoff Harris, & Stan Bukofzer. (2023). OCE-205, A Novel, Selective Vasopressin Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study in Healthy Volunteers. Clinical Drug Investigation. 43(9). 709–717. 3 indexed citations
4.
Bukofzer, Stan, Geoff Harris, & Edward E. Cable. (2023). OCE-205 in rats and non-human primates: Pharmacokinetic and pharmacodynamic analysis. SHILAP Revista de lepidopterología. 5. 100163–100163. 2 indexed citations
5.
Croston, Glenn, et al.. (2023). Selective Partial Agonism of Vasopressin 1a Receptors In Vitro by OCE-205. Journal of Pharmacology and Pharmacotherapeutics. 14(1). 54–61. 3 indexed citations
6.
Safadi, Rifaat, Robert S. Rahimi, Dominique Thabut, et al.. (2022). Pharmacokinetics/pharmacodynamics of L‐ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes. Clinical and Translational Science. 15(6). 1449–1459. 10 indexed citations
7.
Rahimi, Robert S., Rifaat Safadi, Dominique Thabut, et al.. (2020). Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial. Clinical Gastroenterology and Hepatology. 19(12). 2626–2635.e7. 43 indexed citations
8.
Stravitz, R. Todd, Michelle Gottfried, Valerie Durkalski, et al.. (2017). Safety, tolerability, and pharmacokinetics of l‐ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia. Hepatology. 67(3). 1003–1013. 27 indexed citations
9.
Thompson, Randall C., et al.. (2014). Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: a prospective, randomized, multicenter study. International journal of cardiac imaging. 30(5). 979–989. 18 indexed citations
10.
Zinner, Norman R., et al.. (2012). Finding unrecognized information in overactive bladder clinical trial data: A new approach to understanding placebo and treatment effects. Neurourology and Urodynamics. 32(4). 308–313. 2 indexed citations
11.
Johnston, Stephen S., et al.. (2012). Comparative persistence and adherence to overactive bladder medications in patients with and without diabetes. International Journal of Clinical Practice. 66(11). 1042–1051. 15 indexed citations
12.
13.
Ananthasubramaniam, Karthik, et al.. (2012). A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease. Journal of Nuclear Cardiology. 19(2). 319–329. 32 indexed citations
14.
15.
16.
Bukofzer, Stan, et al.. (2001). Safety and tolerability of apomorphine SL (Uprima®). International Journal of Impotence Research. 13(S3). S40–S44. 20 indexed citations
17.
Dula, Eugene, Stan Bukofzer, Renee Perdok, & Michael George. (2001). Double–Blind, Crossover Comparison of 3 mg Apomorphine SL with Placebo and with 4 mg Apomorphine SL in Male Erectile Dysfunction. European Urology. 39(5). 558–564. 104 indexed citations
18.
Whitelaw, S, I. Tomlinson, H. J. W. Thomas, et al.. (1997). Clinical and molecular features of the hereditary mixed polyposis syndrome. Gastroenterology. 112(2). 327–334. 100 indexed citations
19.
Kramvis, Anna, Stan Bukofzer, Michael C. Kew, & E Song. (1997). Nucleic Acid Sequence Analysis of the Precore Region of Hepatitis B Virus From Sera of Southern African Black Adult Carriers of the Virus. Hepatology. 25(1). 235–240. 45 indexed citations
20.
Bukofzer, Stan, et al.. (1989). Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in southern African blacks. British Journal of Cancer. 59(3). 417–420. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhangyan Lyu Breakdown of academic impact, for papers by K. Beckh Breakdown of academic impact, for papers by Massimo Tartagni Breakdown of academic impact, for papers by Georgina R. Hogg Breakdown of academic impact, for papers by Jens Drube Breakdown of academic impact, for papers by Masakatsu Uchihara Breakdown of academic impact, for papers by Jianwei Chen Breakdown of academic impact, for papers by Socrate Pallio Breakdown of academic impact, for papers by Jakub Ząbek Breakdown of academic impact, for papers by Lothar C. Fuith
Rankless by CCL
2026